SG11201805809WA - Inhibition of protein degradation for improved production - Google Patents
Inhibition of protein degradation for improved productionInfo
- Publication number
- SG11201805809WA SG11201805809WA SG11201805809WA SG11201805809WA SG11201805809WA SG 11201805809W A SG11201805809W A SG 11201805809WA SG 11201805809W A SG11201805809W A SG 11201805809WA SG 11201805809W A SG11201805809W A SG 11201805809WA SG 11201805809W A SG11201805809W A SG 11201805809WA
- Authority
- SG
- Singapore
- Prior art keywords
- msx
- international
- epdx
- eey
- january
- Prior art date
Links
- 230000017854 proteolysis Effects 0.000 title abstract 3
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000037361 pathway Effects 0.000 abstract 2
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 102000044159 Ubiquitin Human genes 0.000 abstract 1
- 108090000848 Ubiquitin Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
- C12N2501/734—Proteases (EC 3.4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275691P | 2016-01-06 | 2016-01-06 | |
| US201662276339P | 2016-01-08 | 2016-01-08 | |
| PCT/EP2017/050259 WO2017118726A1 (en) | 2016-01-06 | 2017-01-06 | Inhibition of protein degradation for improved production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805809WA true SG11201805809WA (en) | 2018-08-30 |
Family
ID=57749976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805809WA SG11201805809WA (en) | 2016-01-06 | 2017-01-06 | Inhibition of protein degradation for improved production |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11320422B2 (zh) |
| EP (1) | EP3400439A1 (zh) |
| JP (1) | JP7049253B2 (zh) |
| KR (1) | KR20180093086A (zh) |
| CN (1) | CN108700568A (zh) |
| IL (1) | IL260369B2 (zh) |
| SG (1) | SG11201805809WA (zh) |
| WO (1) | WO2017118726A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3891278A4 (en) * | 2018-12-04 | 2022-08-31 | Catalent Pharma Solutions, LLC | PROTEIN MANUFACTURE VECTORS |
| CN113195710A (zh) * | 2018-12-06 | 2021-07-30 | 麒麟控股株式会社 | T细胞或nk细胞的制造方法、t细胞或nk细胞的培养用培养基、t细胞或nk细胞的培养方法、维持未分化t细胞的未分化状态的方法和t细胞或nk细胞的增殖促进剂 |
| WO2022223505A1 (en) | 2021-04-19 | 2022-10-27 | Sandoz Ag | Control of n-terminal truncation by methionine supplementation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8702550D0 (sv) | 1987-06-18 | 1987-06-18 | Anders Grubb | Cysteinproteashemmare |
| IL97428A0 (en) | 1990-03-05 | 1992-06-21 | Cephalon Inc | Chymotrypsin-like proteases and their inhibitors |
| DE4023465A1 (de) | 1990-07-24 | 1992-02-06 | Andrae Hans Peter | Turmbauwerk |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| JPH06504547A (ja) | 1990-12-28 | 1994-05-26 | ジョージア・テック・リサーチ・コーポレーション | ペプチドケトアミド、ケト酸およびケトエステル |
| US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
| CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| TR200000172T2 (tr) * | 1997-07-23 | 2000-12-21 | Roche Diagnostics Gmbh | Mutasyona uğramış insan proteinlerinin insan hücrelerinde homolog tekrar birleşim ile üretilmesi. |
| EP0943624A1 (en) * | 1998-03-12 | 1999-09-22 | Universiteit Utrecht | Peptidic inhibitors of down-regulation of growth hormone receptor |
| AU782759B2 (en) | 1999-08-20 | 2005-08-25 | Ortho-Mcneil Pharmaceutical, Inc. | Composition comprising a tramadol material and an anticonvulsant drug |
| WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| WO2006002453A2 (en) * | 2004-07-07 | 2006-01-12 | Biodevelops Pharma Entwicklung Gmbh | Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface |
| GB0508880D0 (en) * | 2005-05-03 | 2005-06-08 | Hamlet Pharma Ab | Novel therapies and methods of screening for therapeutic compounds |
| CN104818309B (zh) | 2015-04-28 | 2018-01-19 | 暨南大学 | Mg‑132在cho工程细胞表达外源蛋白中的应用 |
-
2017
- 2017-01-06 WO PCT/EP2017/050259 patent/WO2017118726A1/en active Application Filing
- 2017-01-06 CN CN201780012368.1A patent/CN108700568A/zh active Pending
- 2017-01-06 KR KR1020187022219A patent/KR20180093086A/ko not_active Application Discontinuation
- 2017-01-06 JP JP2018535041A patent/JP7049253B2/ja active Active
- 2017-01-06 SG SG11201805809WA patent/SG11201805809WA/en unknown
- 2017-01-06 US US16/068,422 patent/US11320422B2/en active Active
- 2017-01-06 IL IL260369A patent/IL260369B2/en unknown
- 2017-01-06 EP EP17700086.6A patent/EP3400439A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3400439A1 (en) | 2018-11-14 |
| IL260369B2 (en) | 2024-03-01 |
| WO2017118726A1 (en) | 2017-07-13 |
| US20190120824A1 (en) | 2019-04-25 |
| CN108700568A (zh) | 2018-10-23 |
| JP2019506152A (ja) | 2019-03-07 |
| KR20180093086A (ko) | 2018-08-20 |
| US11320422B2 (en) | 2022-05-03 |
| IL260369B1 (en) | 2023-11-01 |
| JP7049253B2 (ja) | 2022-04-06 |
| IL260369A (en) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
| SG11201807982UA (en) | Substituted inhibitors of menin-mll and methods of use | |
| SG11201805157TA (en) | Targeted disruption of the mhc cell receptor | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201901531TA (en) | Regulation of gene expression using engineered nucleases | |
| SG11201810179RA (en) | Novel crispr enzymes and systems | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201806302RA (en) | Inhibitors of receptor-interacting protein kinase 1 | |
| SG11201804807VA (en) | Computer architecture and method for modifying data intake parameters based on a predictive model | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201900753VA (en) | A method of isolating mesenchymal stem cells from umbilical cord amniotic membrane using a cell culture medium | |
| SG11201808014SA (en) | Compositions, devices, and methods for cell separation | |
| SG11201803983UA (en) | Transformable tagging compositions, methods, and processes incorporating same | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201804162WA (en) | Compositions comprising bacterial strains | |
| SG11201807134RA (en) | Transposon system and methods of use | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201805040UA (en) | Cell reprogramming | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201908784TA (en) | Improved antigen binding receptor formats | |
| SG11201805939QA (en) | Localized temporal model forecasting | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201807881VA (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
| SG11201808992UA (en) | Compositions and methods for the detection of host cell proteins |